Experimental pill tested to boost radiation against head & neck cancer
NCT ID NCT01783587
Summary
This early-phase study tested whether adding an experimental pill called afatinib to standard radiation therapy (with or without chemotherapy) was safe for people who had surgery for head and neck cancer. The main goal was to find the highest dose of afatinib that patients could tolerate without severe side effects when combined with their regular post-surgery treatments. It involved 29 participants who had either an intermediate or high risk of their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.